Hypertension

Disclaimer: This document provides comprehensive, evidence-based medical information for educational purposes and as a clinical reference. It is not a substitute for professional medical advice, diagnosis, or treatment. Clinical decisions must always be made by a qualified healthcare professional, considering the individual patient's circumstances, clinical judgment, and the most current available evidence. This information is subject to change as medical knowledge evolves.

Overview

• Definition: Hypertension (HTN), commonly known as high blood pressure, is a chronic medical condition characterized by persistently elevated blood pressure in the arteries. Blood pressure is the force exerted by circulating blood against the walls of the body's arteries, the major blood vessels.
  • ACC/AHA 2017 Guidelines Classification:
    • Normal: Systolic < 120 mmHg AND Diastolic < 80 mmHg
    • Elevated: Systolic 120-129 mmHg AND Diastolic < 80 mmHg
    • Stage 1 Hypertension: Systolic 130-139 mmHg OR Diastolic 80-89 mmHg
    • Stage 2 Hypertension: Systolic ≥ 140 mmHg OR Diastolic ≥ 90 mmHg
    • Hypertensive Crisis: Systolic > 180 mmHg AND/OR Diastolic > 120 mmHg
• Epidemiology:
  • Globally, HTN is the leading preventable cause of premature death and disability.
  • Affects approximately one-third of the adult population worldwide.
  • Prevalence: In the United States, about half of adults (nearly 116 million people) have hypertension according to the ACC/AHA 2017 guidelines. Only about 1 in 4 adults with HTN have their condition controlled.
  • Increases with age; over 70% of individuals aged 65 and older have HTN.
  • Higher prevalence and severity among certain racial/ethnic groups, particularly non-Hispanic Black adults.
  • Significant regional variations in prevalence and control rates exist globally.
• Classification:
  • Primary (Essential) Hypertension: Accounts for 90-95% of cases. No identifiable secondary cause; likely multifactorial, involving genetic and environmental factors.
  • Secondary Hypertension: Accounts for 5-10% of cases. Caused by an underlying, identifiable, and often reversible condition. Common causes include:
    • Renal parenchymal disease
    • Renal artery stenosis (fibromuscular dysplasia, atherosclerosis)
    • Primary aldosteronism
    • Obstructive sleep apnea
    • Thyroid disorders (hypo- or hyperthyroidism)
    • Parathyroid disease (hypercalcemia)
    • Cushing's syndrome
    • Pheochromocytoma
    • Coarctation of the aorta
    • Drug-induced (e.g., NSAIDs, oral contraceptives, decongestants, steroids, illicit drugs like cocaine, amphetamines).
  • Hypertensive Urgency: Severe elevation in BP (Systolic > 180 mmHg and/or Diastolic > 120 mmHg) without evidence of acute or progressive target organ damage. Requires BP reduction over hours to days.
  • Hypertensive Emergency: Severe elevation in BP (Systolic > 180 mmHg and/or Diastolic > 120 mmHg) accompanied by acute or ongoing target organ damage (e.g., encephalopathy, intracerebral hemorrhage, acute myocardial infarction, unstable angina, acute heart failure, aortic dissection, acute renal failure, eclampsia). Requires immediate (within minutes to hours) BP reduction, usually with IV agents.
  • White Coat Hypertension: Elevated BP readings in a clinical setting but normal readings outside the clinic (e.g., at home or with ABPM).
  • Masked Hypertension: Normal BP readings in a clinical setting but elevated readings outside the clinic. Associated with increased cardiovascular risk.

Pathophysiology

• Mechanism: Hypertension is a complex disorder influenced by interactions between genetic predisposition and environmental factors, leading to dysfunction in several key regulatory systems:
  • Renin-Angiotensin-Aldosterone System (RAAS): Overactivity of RAAS leads to increased angiotensin II (a potent vasoconstrictor and stimulator of aldosterone release) and aldosterone (promotes sodium and water retention), resulting in increased peripheral resistance and blood volume.
  • Sympathetic Nervous System (SNS): Increased SNS activity leads to elevated heart rate, cardiac contractility, and peripheral vasoconstriction, raising systemic vascular resistance.
  • Endothelial Dysfunction: Impaired endothelial function reduces the production of vasodilators (e.g., nitric oxide) and increases production of vasoconstrictors (e.g., endothelin-1), contributing to increased vascular tone and remodeling.
  • Renal Sodium Handling: Impaired renal pressure natriuresis, where the kidneys inappropriately retain sodium and water at higher blood pressures, contributes to increased blood volume.
  • Vascular Remodeling: Long-standing elevated pressure leads to structural changes in blood vessels (hypertrophy, fibrosis, stiffening), which further increases peripheral vascular resistance and perpetuates HTN.
  • Genetic Factors: Polygenic inheritance contributes to essential hypertension susceptibility. Specific gene variants can influence RAAS components, sodium channels, and vascular tone.
  • Inflammation and Oxidative Stress: Chronic low-grade inflammation and increased oxidative stress contribute to endothelial dysfunction and vascular remodeling.
• Risk Factors:
  • Non-modifiable:
    • Age: Risk increases with age, particularly isolated systolic hypertension in older adults.
    • Family History/Genetics: Higher risk if parents or close relatives have HTN.
    • Race/Ethnicity: African Americans tend to develop HTN earlier, with more severe forms, and higher rates of associated complications.
    • Sex: More common in men before age 55; more common in women after age 70.
  • Modifiable:
    • Obesity/Overweight: Strongest modifiable risk factor. Increased adipose tissue, sympathetic activation, and RAAS activation.
    • Unhealthy Diet: High sodium intake, low potassium intake, high saturated/trans fats, low fruit/vegetable intake.
    • Physical Inactivity: Sedentary lifestyle.
    • Excessive Alcohol Consumption: >2 drinks/day for men, >1 drink/day for women.
    • Smoking: Damages blood vessel lining, promotes atherosclerosis.
    • Dyslipidemia: High LDL-cholesterol, low HDL-cholesterol.
    • Diabetes Mellitus: Insulin resistance, endothelial dysfunction.
    • Stress: Chronic psychological stress can transiently increase BP and may contribute to long-term HTN.
    • Certain Medications: NSAIDs, oral contraceptives, corticosteroids, sympathomimetics (decongestants), cyclosporine, tacrolimus, erythropoietin, some antidepressants.
• Protective Factors:
  • Healthy Diet: Emphasizing fruits, vegetables, whole grains, lean protein, and low-fat dairy (e.g., DASH diet).
  • Regular Physical Activity: At least 150 minutes of moderate-intensity aerobic exercise or 75 minutes of vigorous-intensity aerobic exercise per week.
  • Maintaining a Healthy Weight: Body Mass Index (BMI) between 18.5-24.9 kg/m².
  • Sodium Restriction: Limiting dietary sodium intake to <2300 mg/day (ideally <1500 mg/day for most adults).
  • Moderate Alcohol Consumption: Limiting to ≤2 drinks/day for men and ≤1 drink/day for women.
  • Smoking Cessation: Avoidance of tobacco products.
  • Stress Management Techniques: Mindfulness, meditation, yoga.

Clinical Presentation

Signs and Symptoms

• Cardinal Features: Hypertension is often asymptomatic, earning it the moniker "the silent killer." It is frequently discovered during routine medical check-ups.
• Early Signs: Typically none. Initial manifestation is often an incidental elevated BP reading.
• Advanced Signs: Symptoms, when present, usually indicate severe hypertension or target organ damage:
  • Headache: Severe, throbbing, often occipital, worse in the morning. More common in hypertensive crises.
  • Dizziness/Lightheadedness: Non-specific, but can occur.
  • Visual Disturbances: Blurred vision, diplopia, reduced acuity (due to hypertensive retinopathy).
  • Epistaxis (Nosebleeds): More common in severe or poorly controlled HTN.
  • Chest Pain: Angina or symptoms of acute coronary syndrome (ACS).
  • Dyspnea: Shortness of breath, especially on exertion, orthopnea, paroxysmal nocturnal dyspnea (signs of heart failure or pulmonary edema).
  • Palpitations: Awareness of heartbeats.
  • Fatigue, Weakness.
  • Nocturia: Increased urination at night (may indicate kidney involvement).
  • Peripheral Edema: Swelling in legs, ankles (heart failure, kidney disease).
  • Neurological Symptoms: Numbness, tingling, weakness, speech difficulties, altered mental status (stroke, TIA, hypertensive encephalopathy).
• Atypical Presentations:
  • Hypertensive Encephalopathy: Severe headache, confusion, seizures, altered consciousness, focal neurological deficits (reversible).
  • Aortic Dissection: Sudden, severe, tearing chest or back pain, often radiating.
  • Pheochromocytoma: Episodic "spells" of headache, sweating, palpitations, and anxiety.
  • Primary Aldosteronism: Muscle weakness, fatigue, polyuria, nocturia due to hypokalemia.

Physical Examination

• Inspection:
  • General Appearance: Obesity, signs of Cushing's syndrome (moon facies, buffalo hump, striae), pallor (anemia in CKD).
  • Fundoscopy: Essential for assessing hypertensive retinopathy (arteriolar narrowing, AV nicking, hemorrhages, exudates, papilledema in severe cases).
  • Neck: Jugular venous distension (heart failure), thyroid enlargement.
  • Lower Extremities: Edema, signs of peripheral artery disease (skin changes, hair loss).
• Palpation:
  • Blood Pressure Measurement: Crucial. Use appropriate cuff size. Take in both arms initially; higher reading arm should be used for subsequent measurements. Measure BP after 5 minutes of rest, seated, feet flat on floor, arm supported at heart level.
  • Pulses: Radial, femoral, and pedal pulses. Assess for symmetry, presence, and delay (e.g., radiofemoral delay suggesting coarctation of the aorta).
  • Heart: Apex beat for displacement (LVH).
  • Kidneys: Rarely palpable, but check for masses.
• Auscultation:
  • Heart: S4 gallop (LVH), S3 gallop (heart failure), murmurs (aortic stenosis, coarctation).
  • Lungs: Rales/crackles (pulmonary edema, heart failure).
  • Abdomen: Renal bruits (suggests renal artery stenosis), especially epigastric.
  • Carotid Bruits: Suggestive of atherosclerotic disease.
  • Femoral Bruits: Suggestive of peripheral artery disease.
• Special Tests: Fundoscopic examination is paramount for assessing end-organ damage. Neurological examination (e.g., for focal deficits) if encephalopathy or stroke is suspected.

Diagnostic Approach

History Taking

• Key Questions:
  • Duration and Severity: When was HTN first diagnosed? What were the initial readings? What is the current control status?
  • Previous Readings: Any historical BP measurements (e.g., from health screenings, previous visits).
  • Symptoms: Any symptoms suggestive of HTN or target organ damage (headache, dizziness, visual changes, chest pain, dyspnea, leg swelling, nocturia, weakness, numbness, confusion)?
  • Family History: Parents or siblings with HTN, heart disease, stroke, kidney disease at a young age?
  • Lifestyle: Dietary habits (sodium intake, fast food), physical activity level, smoking status (current/past, packs/year), alcohol consumption (type, frequency, amount), illicit drug use (cocaine, amphetamines).
  • Current Medications: Prescription, over-the-counter (OTC), herbal supplements (e.g., NSAIDs, decongestants, oral contraceptives, steroids, cyclosporine, tacrolimus, MAOIs).
  • Comorbidities: Diabetes, dyslipidemia, kidney disease, thyroid disease, sleep apnea, heart disease, stroke.
  • Symptoms of Secondary Hypertension:
    • Paroxysmal HTN with sweating, headache, palpitations: Pheochromocytoma.
    • Muscle weakness, polyuria, nocturia, cramps: Primary aldosteronism (hypokalemia).
    • Snoring, daytime somnolence, witnessed apneas: Obstructive sleep apnea.
    • Weight gain, central obesity, striae, easy bruising: Cushing's syndrome.
    • Cold intolerance, fatigue, constipation, weight gain: Hypothyroidism.
    • Heat intolerance, weight loss, palpitations, tremor: Hyperthyroidism.
    • Sudden onset or worsening HTN in young age, or resistant HTN: Renal artery stenosis, coarctation.
• Red Flags:
  • Sudden onset or rapidly accelerating HTN.
  • Severe headache, visual changes, neurological deficits, chest pain, dyspnea, altered mental status: Suggests hypertensive emergency and end-organ damage.
  • Age < 30 years with severe HTN without obvious risk factors.
  • Refractory hypertension (uncontrolled despite ≥3 antihypertensive agents from different classes, including a diuretic).
  • Significant electrolyte abnormalities (e.g., spontaneous hypokalemia).

Laboratory Tests

• First-Line (Routine Initial Workup for Newly Diagnosed HTN):
  • Complete Blood Count (CBC): Baseline, check for anemia.
  • Basic Metabolic Panel (BMP):
    • Electrolytes (Sodium, Potassium, Chloride, Bicarbonate): To screen for primary aldosteronism (hypokalemia), assess renal function, and baseline before diuretic therapy.
    • Blood Urea Nitrogen (BUN) and Creatinine: Assess kidney function.
    • Estimated Glomerular Filtration Rate (eGFR): Quantify kidney function.
    • Glucose: Screen for diabetes or pre-diabetes (common comorbidity).
  • Lipid Panel (Fasting): Total cholesterol, HDL-C, LDL-C, triglycerides. Assess cardiovascular risk.
  • Thyroid Stimulating Hormone (TSH): Screen for thyroid dysfunction.
  • Urinalysis (UA): Proteinuria, hematuria, casts (suggestive of kidney disease).
  • Electrocardiogram (ECG): Assess for left ventricular hypertrophy (LVH), prior myocardial infarction, arrhythmias, or conduction abnormalities.
• Confirmatory:
  • Ambulatory Blood Pressure Monitoring (ABPM): Gold standard for confirming diagnosis of sustained hypertension and differentiating white coat HTN from masked HTN. Provides average BP over 24 hours, night-time dipping status.
    • Diagnostic criteria for HTN by ABPM:
      • 24-hour average ≥ 125/75 mmHg
      • Daytime (awake) average ≥ 130/80 mmHg
      • Nighttime (sleep) average ≥ 110/65 mmHg
  • Home Blood Pressure Monitoring (HBPM): Recommended for all patients with HTN. More practical and affordable than ABPM. Also useful for diagnosis and monitoring.
    • Diagnostic criteria for HTN by HBPM: Average readings ≥ 135/85 mmHg.
• Monitoring (Ongoing):
  • BMP (electrolytes, creatinine): Periodically after starting/adjusting medications, especially diuretics, ACEi/ARBs.
  • Fasting Glucose, Lipid Panel: Annually or as indicated by glycemic/lipid control.
• For Secondary Hypertension (if clinical suspicion arises):
  • Plasma Aldosterone/Renin Ratio (ARR): Screening for primary aldosteronism.
  • 24-hour Urinary Metanephrines and Normetanephrines / Plasma Free Metanephrines: Screening for pheochromocytoma.
  • Serum Cortisol (morning, midnight, or Dexamethasone Suppression Test): Cushing's syndrome.
  • Renal Artery Duplex Ultrasound: Screening for renal artery stenosis.
  • Polysomnography (Sleep Study): Obstructive sleep apnea.

Imaging

• Recommended (Routine):
  • Electrocardiogram (ECG): As noted above, to assess for LVH, ischemia, or arrhythmias.
  • Chest X-ray: (Less commonly routine, but useful if heart failure or cardiomegaly is suspected).
• Advanced (Indicated for specific situations or suspected secondary causes/complications):
  • Echocardiogram: To evaluate for LVH (more sensitive than ECG), diastolic dysfunction, valvular heart disease, or heart failure. Recommended for patients with signs/symptoms of heart disease or advanced LVH on ECG.
  • Renal Artery Duplex Ultrasound: For suspected renal artery stenosis (e.g., young patient with severe HTN, sudden worsening, abdominal bruit, unexplained renal failure after ACEi/ARB initiation).
  • CT Angiography (CTA) or Magnetic Resonance Angiography (MRA) of Renal Arteries: More definitive for renal artery stenosis, especially if duplex is inconclusive or suspicion is high.
  • Abdominal CT/MRI: For adrenal masses (pheochromocytoma, aldosteronoma, Cushing's).
  • Brain CT/MRI: For neurological symptoms (stroke, hypertensive encephalopathy, intracranial hemorrhage).
  • Aortic CTA/MRA: For suspected aortic dissection.

Management

Acute Management

• Immediate: Identify if it's a hypertensive urgency or emergency.
  • Hypertensive Urgency: No acute end-organ damage. Goal is to lower BP gradually over 24-48 hours. Oral agents are typically used (e.g., captopril, labetalol, clonidine, amlodipine). Rapid BP reduction can cause hypoperfusion.
  • Hypertensive Emergency: Acute, life-threatening target organ damage. Requires immediate intravenous antihypertensive therapy in an ICU setting.
• Stabilization (Hypertensive Emergency):
  • Goals: Reduce Mean Arterial Pressure (MAP) by no more than 20-25% within the first hour. Then, if stable, reduce BP towards 160/100 mmHg over the next 2-6 hours. Exceptions:
    • Acute Aortic Dissection: Goal is rapid reduction of SBP to <120 mmHg within 20 minutes (with heart rate control).
    • Acute Ischemic Stroke: BP reduction generally avoided unless SBP >220 mmHg or DBP >120 mmHg (if no thrombolysis) or SBP >185 mmHg or DBP >110 mmHg (if thrombolysis candidate).
    • Intracerebral Hemorrhage: Target SBP 140-160 mmHg.
  • Monitor: Continuous BP monitoring, neurological status, urine output, ECG.
• Emergency (IV Agents for Hypertensive Emergency):
  • Nicardipine: 5-15 mg/hour IV infusion. Potent peripheral vasodilator. Good for most emergencies.
  • Labetalol: 20 mg IV bolus, then 20-80 mg every 10 min or 0.5-2 mg/min IV infusion. Beta-blocker and alpha-blocker. Good for most emergencies, especially aortic dissection, preeclampsia. Avoid in acute heart failure or asthma/COPD.
  • Clevidipine: 1-32 mg/hour IV infusion. Ultra-short acting CCB.
  • Esmolol: 250-500 mcg/kg loading dose, then 50-300 mcg/kg/min IV infusion. Ultra-short acting beta-blocker. Good for aortic dissection, perioperative HTN.
  • Sodium Nitroprusside: 0.25-10 mcg/kg/min IV infusion. Potent arterial and venous vasodilator. Rapid onset and offset. Risk of cyanide toxicity with prolonged use/renal failure. Avoid in increased intracranial pressure.
  • Fenoldopam: 0.1-1.6 mcg/kg/min IV infusion. Dopamine-1 agonist, peripheral vasodilator. Renal protective.
  • Hydralazine: 10-20 mg IV bolus every 4-6 hours. Direct vasodilator. Slower onset, unpredictable. Often used in pregnancy.
  • Nitroglycerin: 5-200 mcg/min IV infusion. Venodilator (at low doses), arterial vasodilator (at high doses). Good for acute coronary syndrome, acute pulmonary edema.

Chronic Management

• Target BP:
  • General Adult Population (ACC/AHA 2017): <130/80 mmHg.
  • Older Adults (≥65 years): Same target (<130/80 mmHg), but individualize based on frailty, comorbidities, and risk of adverse effects (e.g., orthostatic hypotension). SBP target of <130 mmHg is reasonable for non-frail, community-dwelling older adults.
  • CKD or Diabetes: <130/80 mmHg.
• Pharmacological:
  • First-Line Classes (ACC/AHA 2017): Thiazide diuretics, ACE inhibitors (ACEi), Angiotensin Receptor Blockers (ARBs), and Calcium Channel Blockers (CCBs).
    • Initiation:
      • Stage 1 HTN (130-139/80-89 mmHg): Lifestyle modifications first. If ASCVD risk <10%, reconsider medication after 3-6 months. If ASCVD risk ≥10% or history of clinical ASCVD, initiate medication + lifestyle.
      • Stage 2 HTN (≥140/90 mmHg): Initiate combination of two first-line agents, or a single agent if BP is only slightly above target (e.g., 140/90 mmHg), plus lifestyle modifications.
    • Specific Agents and Doses (Examples):
      • Thiazide Diuretics: Hydrochlorothiazide (HCTZ) 12.5-25 mg daily (max 50 mg), Chlorthalidone 12.5-25 mg daily (more potent, longer duration), Indapamide 1.25-2.5 mg daily. Mechanism: Inhibit Na/Cl reabsorption in distal convoluted tubule. Side Effects: Hypokalemia, hyponatremia, hyperuricemia, hyperglycemia.
      • ACE Inhibitors: Lisinopril 10-40 mg daily, Enalapril 5-40 mg daily/BID, Ramipril 2.5-20 mg daily. Mechanism: Block conversion of Angiotensin I to Angiotensin II, reduce bradykinin breakdown. Side Effects: Cough, angioedema, hyperkalemia, renal impairment (esp. with bilateral renal artery stenosis). Contraindicated in pregnancy.
      • Angiotensin Receptor Blockers (ARBs): Losartan 25-100 mg daily, Valsartan 80-320 mg daily, Olmesartan 20-40 mg daily. Mechanism: Block Angiotensin II at AT1 receptor. Side Effects: Hyperkalemia, renal impairment. Lower incidence of cough/angioedema than ACEi. Contraindicated in pregnancy.
      • Calcium Channel Blockers (CCBs):
        • Dihydropyridines: Amlodipine 2.5-10 mg daily, Nifedipine XL 30-90 mg daily. Mechanism: Primarily peripheral vasodilation. Side Effects: Peripheral edema, headache, flushing, reflex tachycardia.
        • Non-dihydropyridines: Verapamil 180-480 mg daily (SR), Diltiazem 120-360 mg daily (ER). Mechanism: Reduce heart rate and contractility, peripheral vasodilation. Side Effects: Bradycardia, AV block, constipation (verapamil). Avoid in heart failure with reduced ejection fraction.
  • Second-Line/Add-on Classes:
    • Beta-Blockers: Metoprolol succinate 25-200 mg daily, Carvedilol 6.25-25 mg BID, Bisoprolol 2.5-10 mg daily. Mechanism: Reduce heart rate, contractility, renin release. Side Effects: Bradycardia, fatigue, bronchospasm, masked hypoglycemia. Preferred for patients with CAD, heart failure with reduced EF, or specific arrhythmias.
    • Alpha-Blockers: Doxazosin 1-8 mg daily, Terazosin 1-20 mg daily. Mechanism: Peripheral vasodilation. Side Effects: Orthostatic hypotension (first-dose syncope), dizziness. Often used for HTN with BPH.
    • Loop Diuretics: Furosemide 20-80 mg daily/BID, Bumetanide 0.5-2 mg daily/BID. Mechanism: Potent diuresis. Primarily for volume overload (heart failure, CKD).
    • Mineralocorticoid Receptor Antagonists (MRAs): Spironolactone 25-50 mg daily, Eplerenone 25-50 mg daily. Mechanism: Block aldosterone. Side Effects: Hyperkalemia, gynecomastia (spironolactone). Useful in resistant HTN, primary aldosteronism, heart failure.
    • Direct Vasodilators: Hydralazine 25-100 mg BID-QID, Minoxidil 2.5-40 mg daily/BID. Mechanism: Direct arterial smooth muscle relaxation. Side Effects: Reflex tachycardia, fluid retention, lupus-like syndrome (hydralazine), hirsutism (minoxidil). Usually used with beta-blocker and diuretic.
    • Central Alpha-2 Agonists: Clonidine 0.1-0.8 mg BID (oral), Methyldopa 250-1000 mg BID-TID. Mechanism: Reduce sympathetic outflow. Side Effects: Sedation, dry mouth, rebound hypertension (if abruptly stopped). Methyldopa for pregnancy.
• Non-pharmacological: Foundation of HTN management.
  • Dietary Approaches to Stop Hypertension (DASH) Diet: Emphasizes fruits, vegetables, whole grains, lean protein, nuts, seeds, and low-fat dairy. Limits red meat, added sugars, saturated/trans fats. Shown to significantly lower BP.
  • Sodium Restriction: Limit intake to <2300 mg/day (ideally <1500 mg/day for most adults with HTN). Avoid processed foods, limit restaurant meals.
  • Potassium Supplementation: Increase intake of potassium-rich foods (fruits, vegetables), unless contraindicated (e.g., advanced CKD, concurrent ACEi/ARB).
  • Weight Management: Maintain a healthy BMI (18.5-24.9 kg/m²). For every 10 kg weight loss, SBP can decrease by 5-20 mmHg.
  • Regular Physical Activity: At least 150 minutes/week of moderate-intensity aerobic activity (e.g., brisk walking) or 75 minutes/week of vigorous-intensity aerobic activity. Add dynamic resistance exercise 2-3 times/week. Can lower BP by 4-12 mmHg.
  • Alcohol Moderation: Limit to ≤2 drinks/day for men and ≤1 drink/day for women. Excessive intake can increase BP.
  • Smoking Cessation: Crucial for overall cardiovascular health. Smoking cessation alone does not directly lower BP but significantly reduces overall cardiovascular risk.
  • Stress Reduction: Techniques like meditation, yoga, mindfulness can complement other therapies.
• Monitoring:
  • Regular BP Measurements: In-office, but especially with HBPM. Goal is to check daily or weekly until controlled, then monthly or quarterly.
  • Adherence Assessment: Discuss medication adherence, lifestyle changes.
  • Side Effect Monitoring: Query for medication side effects.
  • Laboratory Monitoring: As per pharmacological agent side effect profiles (e.g., electrolytes with diuretics/RAAS inhibitors, renal function).
  • Assessment for End-Organ Damage: Periodic evaluation for LVH, CKD progression, retinopathy, and other complications.

Treatment Algorithms

• First-Line (ACC/AHA 2017):
  • Lifestyle modification for ALL patients.
  • Elevated BP (120-129/<80): Non-pharmacological therapy only. Reassess in 3-6 months.
  • Stage 1 HTN (130-139/80-89):
    • ASCVD risk <10%: Non-pharmacological therapy. Reassess in 3-6 months. If BP remains elevated, consider medication.
    • ASCVD risk ≥10% OR established ASCVD/diabetes/CKD: Non-pharmacological therapy + initiate one first-line agent (thiazide, ACEi/ARB, or CCB). Reassess in 1 month.
  • Stage 2 HTN (≥140/90): Non-pharmacological therapy + initiate two first-line agents (preferably from different classes, e.g., ACEi/ARB + CCB, or ACEi/ARB + thiazide diuretic). Reassess in 1 month.
• Second-Line:
  • If BP target not met after 1 month on initial therapy, either:
    • Increase dose of current agent(s).
    • Add a second (or third) agent from a different first-line class.
    • Common combinations: ACEi/ARB + CCB; ACEi/ARB + Thiazide; CCB + Thiazide. Fixed-dose combination pills can improve adherence.
  • Consider different combinations or adding beta-blocker, alpha-blocker, or MRA if two agents are insufficient and there are compelling indications.
• Refractory Cases (Resistant Hypertension):
  • Defined as BP remaining above target despite adherence to optimal doses of 3 antihypertensive agents from different classes, including a diuretic.
  • Key Steps:
    1. Rule out Pseudo-resistance:
       • Improper BP Measurement: Incorrect cuff size, arm not supported, white coat effect. Use ABPM/HBPM to confirm true resistant HTN.
       • Medication Non-Adherence: Crucial to address.
    2. Rule out Secondary Causes: Re-evaluate for all secondary causes (renal artery stenosis, primary aldosteronism, pheochromocytoma, OSA, etc.).
    3. Optimize Diuretic Therapy: Ensure diuretic is effective. Chlorthalidone often preferred over HCTZ due to longer half-life. Consider adding loop diuretic if CKD Stage 4 or 5.
    4. Add a Mineralocorticoid Receptor Antagonist (MRA): Spironolactone (25-50 mg daily) or Eplerenone (25-50 mg daily) are often effective as a fourth-line agent.
    5. Consider other agents: Beta-blockers, alpha-blockers, direct vasodilators (hydralazine, minoxidil).
    6. Referral to Hypertension Specialist: For complex or truly refractory cases.

Complications

• Common:
  • Left Ventricular Hypertrophy (LVH): Heart muscle thickens to compensate for increased workload, leading to reduced diastolic filling and eventual systolic dysfunction.
  • Chronic Kidney Disease (CKD): Progressive damage to renal arteries and nephrons, leading to impaired kidney function.
  • Hypertensive Retinopathy: Damage to retinal blood vessels, leading to visual impairment.
  • Peripheral Artery Disease (PAD): Atherosclerosis in peripheral arteries, often in the legs.
• Serious (Life-threatening or major morbidity):
  • Stroke: Both ischemic (due to atherosclerosis and thrombus formation) and hemorrhagic (due to rupture of cerebral arteries, e.g., Charcot-Bouchard aneurysms). HTN is the strongest modifiable risk factor for stroke.
  • Myocardial Infarction (MI): Increased demand on the heart and accelerated atherosclerosis of coronary arteries.
  • Heart Failure with Preserved Ejection Fraction (HFpEF): Due to LVH and diastolic dysfunction.
  • Heart Failure with Reduced Ejection Fraction (HFrEF): Due to chronic pressure overload leading to LV remodeling and systolic dysfunction.
  • Aortic Dissection: Tearing of the inner layer of the aorta, often precipitated by sudden, severe BP elevation.
  • Hypertensive Encephalopathy: A medical emergency characterized by cerebral edema and neurological dysfunction due to severe, rapid BP elevation.
  • Acute Kidney Injury (AKI): Can occur during hypertensive emergencies.
  • Pre-eclampsia/Eclampsia: Potentially life-threatening complications of pregnancy.
• Long-term:
  • End-Stage Renal Disease (ESRD): Requires dialysis or kidney transplant.
  • Blindness: Due to severe, prolonged hypertensive retinopathy.
  • Vascular Dementia/Cognitive Impairment: Due to chronic microvascular damage in the brain.
  • Increased risk of premature death from cardiovascular causes.

Prognosis

• Factors:
  • Level of BP Control: Achieving and maintaining target BP significantly improves prognosis.
  • Presence of End-Organ Damage: Existing LVH, CKD, or retinopathy worsens prognosis.
  • Comorbidities: Diabetes, dyslipidemia, obesity, and other cardiovascular risk factors worsen prognosis.
  • Adherence to Treatment: Consistent medication use and lifestyle modifications are critical.
  • Lifestyle Factors: Persistent unhealthy habits (smoking, sedentary life, poor diet) negatively impact outcome.
  • Age at Diagnosis: Earlier onset is associated with longer exposure and potentially more severe end-organ damage.
• Survival:
  • Hypertension is a major contributor to global morbidity and mortality. Untreated or poorly controlled HTN significantly increases the risk of stroke, MI, heart failure, and kidney failure.
  • Effective management of HTN has been shown to reduce the risk of stroke by 35-40%, MI by 20-25%, and heart failure by 50%.
• Quality of Life:
  • Generally good with well-controlled HTN.
  • Can be impaired by symptoms of advanced complications (e.g., dyspnea in HF, neurological deficits post-stroke, need for dialysis in ESRD) or by side effects of medications.
  • The burden of chronic disease management (medication adherence, regular monitoring, lifestyle changes) can also impact quality of life.

Prevention

• Primary Prevention: Aims to prevent the development of hypertension in healthy individuals.
  • Population-Level Strategies: Public health campaigns promoting healthy diet, physical activity, reduced sodium intake.
  • Individual-Level Strategies:
    • Maintain a healthy weight: BMI 18.5-24.9 kg/m².
    • Adopt a DASH-style eating plan: Rich in fruits, vegetables, whole grains; low in saturated/trans fats and cholesterol.
    • Reduce dietary sodium intake: Aim for <2300 mg/day, ideally <1500 mg/day.
    • Engage in regular physical activity: At least 150 minutes of moderate-intensity aerobic exercise or 75 minutes of vigorous-intensity aerobic exercise per week.
    • Moderate alcohol consumption: ≤2 drinks/day for men, ≤1 drink/day for women.
    • Avoid smoking and exposure to secondhand smoke.
    • Manage stress effectively.
• Secondary Prevention: Aims for early detection and prompt intervention in individuals with hypertension to prevent or delay the onset of complications.
  • Routine Blood Pressure Screening: Recommended for all adults at least every 1-2 years, or annually if elevated BP or risk factors. More frequent monitoring for individuals with elevated BP or stage 1 HTN.
  • Prompt Diagnosis and Initiation of Treatment: Implement pharmacological and non-pharmacological therapies as per guidelines once HTN is diagnosed.
  • Regular Follow-up: To ensure BP control, assess for medication adherence, monitor for side effects, and screen for early signs of end-organ damage.
• Tertiary Prevention: Focuses on minimizing the impact of established hypertension and its complications, preventing disease progression, and improving quality of life.
  • Intensive Blood Pressure Control: For patients with established HTN and comorbidities or existing end-organ damage, maintaining strict BP control is vital.
  • Management of Comorbidities: Aggressive management of diabetes, dyslipidemia, and other cardiovascular risk factors.
  • Screening for and Management of End-Organ Damage: Regular screening for LVH, CKD, retinopathy, and other complications, with appropriate interventions if detected.
  • Patient Education and Empowerment: Educating patients about their condition, the importance of adherence, and self-management strategies.

Special Populations

• Pediatric:
  • Definition: HTN in children is defined by age-, sex-, and height-specific BP percentiles. Stage 1: ≥95th percentile to <99th percentile + 5 mmHg. Stage 2: ≥99th percentile + 5 mmHg.
  • Evaluation: Secondary HTN is much more common than in adults (especially in younger children). Thorough workup for underlying causes (renal, cardiac, endocrine).
  • Management: Lifestyle modifications are first-line. Medications (ACEi, ARBs, CCBs, beta-blockers, diuretics) are used for symptomatic HTN, secondary HTN, HTN with organ damage, or HTN unresponsive to lifestyle.
• Geriatric:
  • Prevalence: Very high, especially isolated systolic hypertension (ISH).
  • Considerations: Increased risk of orthostatic hypotension. Higher risk of adverse drug reactions. Polypharmacy is common. Frailty and cognitive status impact treatment goals.
  • Management: Treatment goals may be individualized. ACC/AHA suggests a target of <130/80 mmHg for non-frail older adults. For frail or very old adults, a less intensive target (e.g., SBP <140 mmHg) might be appropriate to avoid adverse effects. Thiazide diuretics and CCBs are often effective.
• Pregnancy:
  • Classification:
    • Pre-existing (Chronic) HTN: HTN present before pregnancy or diagnosed before 20 weeks gestation.
    • Gestational HTN: New onset HTN after 20 weeks gestation without proteinuria or other signs of preeclampsia. Resolves postpartum.
    • Pre-eclampsia: New onset HTN (after 20 weeks) with proteinuria OR new onset HTN with severe features (thrombocytopenia, renal insufficiency, impaired liver function, pulmonary edema, cerebral or visual symptoms).
    • Eclampsia: Seizures in a woman with pre-eclampsia.
  • Management:
    • Chronic HTN in Pregnancy: Goal SBP 120-160 mmHg, DBP 80-105 mmHg.
    • Preferred Agents: Labetalol, Nifedipine (long-acting), Methyldopa.
    • Contraindicated: ACE inhibitors, ARBs, direct renin inhibitors (due to fetal renal toxicity).
    • Preeclampsia/Eclampsia: Requires close monitoring, often hospitalization, and delivery is the definitive treatment. IV labetalol, hydralazine, or oral nifedipine for severe HTN. Magnesium sulfate for seizure prophylaxis/treatment in preeclampsia with severe features/eclampsia.
• Comorbidities:
  • Diabetes Mellitus: ACEi or ARBs are often first-line due to renoprotective effects, especially if albuminuria is present. Target <130/80 mmHg.
  • Chronic Kidney Disease (CKD): ACEi or ARBs are preferred agents to slow progression of kidney disease, particularly if proteinuria is present. Close monitoring of potassium and creatinine. Target <130/80 mmHg.
  • Coronary Artery Disease (CAD)/Heart Failure (HF): Beta-blockers, ACEi/ARBs are first-line (for HFrEF) due to their beneficial effects on cardiac remodeling and outcomes. Diuretics for fluid overload.
  • African Americans: Higher prevalence, more severe HTN, and often less responsive to monotherapy with ACEi/ARBs. Thiazide diuretics and CCBs are generally more effective as initial therapy in this population, either alone or in combination.

Clinical Pearls

• Diagnostic:
  • "The Silent Killer": Always remember that hypertension is usually asymptomatic. Regular screening is essential.
  • Confirm with Multiple Readings: Do not diagnose based on a single high reading. Use average of ≥2 readings on ≥2 separate occasions.
  • ABPM/HBPM is Gold Standard: Crucial for confirming sustained HTN and differentiating white coat or masked HTN. It helps avoid over- or under-treatment.
  • Think Secondary HTN: Especially in young patients, severe or resistant HTN, or those with unusual symptoms (e.g., hypokalemia, paroxysmal events).
• Treatment:
  • Lifestyle First: Emphasize non-pharmacological interventions for all patients. They are foundational.
  • Start Low, Go Slow (but steady): Especially in elderly or frail patients, to avoid orthostatic hypotension or other side effects. However, for Stage 2 HTN, don't delay medication initiation.
  • Combination Therapy is Common: Most patients with HTN will require two or more medications to reach target BP. Fixed-dose combinations can improve adherence.
  • Adherence is Key: Medication adherence is the biggest challenge in HTN management. Educate, simplify regimens, and address barriers.
  • Treat to Target: Don't just start medication; ensure BP reaches and stays within the target range.
  • Individualize Treatment: Consider patient age, comorbidities, race/ethnicity, and preferences when choosing agents.
• Pitfalls:
  • Diagnosing HTN too quickly: Based on one office reading, without confirming with repeat readings or ABPM/HBPM.
  • Ignoring White Coat/Masked HTN: Both are associated with increased cardiovascular risk and require appropriate management/monitoring.
  • Failing to Address Lifestyle: Relying solely on medication without emphasizing diet, exercise, and weight management.
  • Stopping Therapy Abruptly: Especially with beta-blockers or central alpha-agonists (e.g., clonidine) due to risk of rebound hypertension.
  • Not Considering Secondary Causes: Overlooking treatable causes of HTN, leading to persistent uncontrolled BP.
  • Ignoring Orthostatic Hypotension: Especially in older adults or those on multiple medications; can lead to falls.
  • Failure to Monitor Electrolytes/Renal Function: Crucial with diuretics, ACEi, ARBs, MRAs.

Recent Updates

• Guidelines:
  • ACC/AHA 2017 Hypertension Guideline: Major shift in BP classification, lowering the threshold for Stage 1 HTN (130/80 mmHg). Emphasized early intervention with lifestyle modification and defined specific treatment thresholds based on ASCVD risk. Recommended a universal target of <130/80 mmHg for most adults.
  • ESC/ESH 2018 Guidelines for the Management of Arterial Hypertension: Maintained BP classification thresholds similar to previous JNC 7 guidelines (≥140/90 mmHg for HTN), but with a strong emphasis on ABPM/HBPM for diagnosis. Also recommended lower treatment targets (<130/80 mmHg if tolerated, especially for those at high CV risk).
  • NICE Guideline (UK) 2019: Similar to ESC, diagnosing HTN based on clinic BP ≥140/90 mmHg, confirmed with ABPM or HBPM.
• Evidence:
  • SPRINT Trial (Systolic Blood Pressure Intervention Trial, 2015): Demonstrated significant cardiovascular benefits (reduced MI, stroke, HF, cardiovascular death) with intensive BP lowering (SBP target <120 mmHg) compared to standard care (SBP target <140 mmHg) in non-diabetic adults with high cardiovascular risk. This trial heavily influenced the ACC/AHA 2017 guidelines.
  • STEP Trial (Strategy of Blood Pressure Intervention in the Elderly Hypertensive Patients, 2021): Showed that intensive SBP lowering to <130 mmHg was superior to a target of 130-150 mmHg in Chinese elderly patients (60-80 years old) in terms of cardiovascular events.
• Controversies:
  • Optimal BP Targets in the Elderly/Frail: While SPRINT suggested lower targets, the generalizability to very frail or nursing home residents remains debated due to increased risk of falls and orthostatic hypotension. Individualized goals are paramount.
  • Role of Beta-Blockers as First-Line: Most guidelines do not recommend beta-blockers as routine first-line therapy unless there is a compelling indication (e.g., CAD, HFrEF, specific arrhythmias). This is due to concerns about less effective stroke prevention compared to other agents and potential metabolic side effects.
  • Sodium Restriction Levels: While consensus supports sodium restriction, the optimal level remains debated, with some arguing for individualized targets rather than a one-size-fits-all <1500mg/day target for all.

Key References

• Guidelines:
  • Whelton PK, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2018;71(6):e13-e115.
  • Williams B, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH). Eur Heart J. 2018;39(33):3021-3104.
  • NICE Guideline [NG136]: Hypertension in adults: diagnosis and management. Published August 2019. Available from: www.nice.org.uk/guidance/ng136.
• Studies:
  • The SPRINT Research Group. A Randomized Trial of Intensive versus Standard Blood-Pressure Control. N Engl J Med. 2015;373(22):2103-2116.
  • Zhang W, et al. Effect of Intensive Blood Pressure Lowering on Cardiovascular Disease Events in Older Patients With Hypertension: The STEP Randomized Clinical Trial. JAMA. 2021;325(16):1617-1626.
• Reviews/Textbooks:
  • UpToDate: Hypertension: Overview of management in adults. (Accessed regularly for current evidence).
  • Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine. (Comprehensive cardiology reference).
  • Harrison's Principles of Internal Medicine. (Comprehensive internal medicine reference).